Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Immunogenicity and protective efficacy of a Vero cell culture-derived whole-virus H7N9 vaccine in mice and guinea pigs.

Wodal W, Schwendinger MG, Savidis-Dacho H, Crowe BA, Hohenadl C, Fritz R, Brühl P, Portsmouth D, Karner-Pichl A, Balta D, Grillberger L, Kistner O, Barrett PN, Howard MK.

PLoS One. 2015 Feb 26;10(2):e0113963. doi: 10.1371/journal.pone.0113963. eCollection 2015.

2.

Laboratory diagnosis of Lyme neuroborreliosis is influenced by the test used: comparison of two ELISAs, immunoblot and CXCL13 testing.

Wutte N, Archelos J, Crowe BA, Zenz W, Daghofer E, Fazekas F, Aberer E.

J Neurol Sci. 2014 Dec 15;347(1-2):96-103. doi: 10.1016/j.jns.2014.09.027. Epub 2014 Sep 26.

PMID:
25288328
3.

A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu lato.

Wressnigg N, Barrett PN, Pöllabauer EM, O'Rourke M, Portsmouth D, Schwendinger MG, Crowe BA, Livey I, Dvorak T, Schmitt B, Zeitlinger M, Kollaritsch H, Esen M, Kremsner PG, Jelinek T, Aschoff R, Weisser R, Naudts IF, Aichinger G.

Clin Vaccine Immunol. 2014 Nov;21(11):1490-9. doi: 10.1128/CVI.00406-14. Epub 2014 Sep 3.

4.

Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients.

van der Velden MV, Geisberger A, Dvorak T, Portsmouth D, Fritz R, Crowe BA, Herr W, Distler E, Wagner EM, Zeitlinger M, Sauermann R, Stephan C, Ehrlich HJ, Barrett PN, Aichinger G.

Clin Vaccine Immunol. 2014 Jun;21(6):867-76. doi: 10.1128/CVI.00065-14. Epub 2014 Apr 16.

5.

MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses.

Hessel A, Savidis-Dacho H, Coulibaly S, Portsmouth D, Kreil TR, Crowe BA, Schwendinger MG, Pilz A, Barrett PN, Falkner FG, Schäfer B.

PLoS One. 2014 Feb 11;9(2):e88340. doi: 10.1371/journal.pone.0088340. eCollection 2014.

6.

Lyme disease vaccination: safety first - authors' reply.

Barrett PN, Crowe BA, Wressnigg N, Portsmouth D, Aichinger G.

Lancet Infect Dis. 2014 Jan;14(1):12-13. doi: 10.1016/S1473-3099(13)70362-1. No abstract available.

PMID:
24355029
7.

Evaluation of OspA vaccination-induced serological correlates of protection against Lyme borreliosis in a mouse model.

Schwendinger MG, O'Rourke M, Traweger A, Savidis-Dacho H, Pilz A, Portsmouth D, Livey I, Barrett PN, Crowe BA.

PLoS One. 2013 Nov 18;8(11):e79022. doi: 10.1371/journal.pone.0079022. eCollection 2013.

8.

Preclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines.

Smith LR, Wodal W, Crowe BA, Kerschbaum A, Bruehl P, Schwendinger MG, Savidis-Dacho H, Sullivan SM, Shlapobersky M, Hartikka J, Rolland A, Barrett PN, Kistner O.

Hum Vaccin Immunother. 2013 Jun;9(6):1333-45. doi: 10.4161/hv.24209. Epub 2013 Mar 6.

9.

Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial.

Wressnigg N, Pöllabauer EM, Aichinger G, Portsmouth D, Löw-Baselli A, Fritsch S, Livey I, Crowe BA, Schwendinger M, Brühl P, Pilz A, Dvorak T, Singer J, Firth C, Luft B, Schmitt B, Zeitlinger M, Müller M, Kollaritsch H, Paulke-Korinek M, Esen M, Kremsner PG, Ehrlich HJ, Barrett PN.

Lancet Infect Dis. 2013 Aug;13(8):680-9. doi: 10.1016/S1473-3099(13)70110-5. Epub 2013 May 10.

PMID:
23665341
10.

A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination.

Sabarth N, Savidis-Dacho H, Schwendinger MG, Brühl P, Portsmouth D, Crowe BA, Kistner O, Barrett PN, Kreil TR, Howard MK.

Vaccine. 2012 Aug 10;30(37):5533-40. doi: 10.1016/j.vaccine.2012.06.043. Epub 2012 Jun 29.

PMID:
22749797
11.

Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever.

Schäfer B, Holzer GW, Joachimsthaler A, Coulibaly S, Schwendinger M, Crowe BA, Kreil TR, Barrett PN, Falkner FG.

PLoS One. 2011;6(9):e24505. doi: 10.1371/journal.pone.0024505. Epub 2011 Sep 9.

12.

Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity.

Hessel A, Schwendinger M, Holzer GW, Orlinger KK, Coulibaly S, Savidis-Dacho H, Zips ML, Crowe BA, Kreil TR, Ehrlich HJ, Barrett PN, Falkner FG.

PLoS One. 2011 Jan 24;6(1):e16247. doi: 10.1371/journal.pone.0016247.

13.

A new approach to a Lyme disease vaccine.

Livey I, O'Rourke M, Traweger A, Savidis-Dacho H, Crowe BA, Barrett PN, Yang X, Dunn JJ, Luft BJ.

Clin Infect Dis. 2011 Feb;52 Suppl 3:s266-70. doi: 10.1093/cid/ciq118.

PMID:
21217174
14.

Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans.

Crowe BA, Brühl P, Gerencer M, Schwendinger MG, Pilz A, Kistner O, Koelling-Schlebusch K, Aichinger G, Singer J, Zeitlinger M, Müller M, Ehrlich H, Barrett PN.

Vaccine. 2010 Dec 16;29(2):166-73. doi: 10.1016/j.vaccine.2010.10.065. Epub 2010 Nov 4.

PMID:
21055500
15.

A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations.

Hessel A, Schwendinger M, Fritz D, Coulibaly S, Holzer GW, Sabarth N, Kistner O, Wodal W, Kerschbaum A, Savidis-Dacho H, Crowe BA, Kreil TR, Barrett PN, Falkner FG.

PLoS One. 2010 Aug 16;5(8):e12217. doi: 10.1371/journal.pone.0012217.

16.

A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models.

Kistner O, Crowe BA, Wodal W, Kerschbaum A, Savidis-Dacho H, Sabarth N, Falkner FG, Mayerhofer I, Mundt W, Reiter M, Grillberger L, Tauer C, Graninger M, Sachslehner A, Schwendinger M, Brühl P, Kreil TR, Ehrlich HJ, Barrett PN.

PLoS One. 2010 Feb 23;5(2):e9349. doi: 10.1371/journal.pone.0009349.

17.

Seasonal influenza vaccine elicits heterosubtypic immunity against H5N1 that can be further boosted by H5N1 vaccination.

van Maurik A, Sabarth N, Dacho HS, Brühl P, Schwendinger M, Crowe BA, Noel Barrett P, Kistner O, Keith Howard M.

Vaccine. 2010 Feb 17;28(7):1778-85. doi: 10.1016/j.vaccine.2009.12.008. Epub 2009 Dec 16.

PMID:
20018265
18.

Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection.

Mayrhofer J, Coulibaly S, Hessel A, Holzer GW, Schwendinger M, Brühl P, Gerencer M, Crowe BA, Shuo S, Hong W, Tan YJ, Dietrich B, Sabarth N, Savidis-Dacho H, Kistner O, Barrett PN, Falkner FG.

J Virol. 2009 May;83(10):5192-203. doi: 10.1128/JVI.02081-08. Epub 2009 Mar 11.

19.

Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses.

Kistner O, Howard MK, Spruth M, Wodal W, Brühl P, Gerencer M, Crowe BA, Savidis-Dacho H, Livey I, Reiter M, Mayerhofer I, Tauer C, Grillberger L, Mundt W, Falkner FG, Barrett PN.

Vaccine. 2007 Aug 10;25(32):6028-36. Epub 2007 Jun 4.

20.

The role of complement and gp120-specific antibodies in virus lysis and CD4+ T cell depletion in HIV-1-infected patients.

Gerencer M, Burek V, Crowe BA, Barrett NP, Dorner F.

Microb Pathog. 1998 Nov;25(5):253-66.

PMID:
9878454
21.

Clonal and antigenic analysis of serogroup A Neisseria meningitidis with particular reference to epidemiological features of epidemic meningitis in the People's Republic of China.

Wang JF, Caugant DA, Li X, Hu X, Poolman JT, Crowe BA, Achtman M.

Infect Immun. 1992 Dec;60(12):5267-82. Erratum in: Infect Immun 1994 Dec;62(12):5706.

22.

The first clinical trial of immuno's experimental Pseudomonas aeruginosa flagellar vaccines.

Crowe BA, Enzersberger O, Schober-Bendixen S, Mitterer A, Mundt W, Livey I, Pabst H, Kaeser R, Eibl M, Eibl J, et al.

Antibiot Chemother (1971). 1991;44:143-56. No abstract available.

PMID:
1801633
23.

Clonal and variable properties of Neisseria meningitidis isolated from cases and carriers during and after an epidemic in The Gambia, West Africa.

Crowe BA, Wall RA, Kusecek B, Neumann B, Olyhoek T, Abdillahi H, Hassan-King M, Greenwood BM, Poolman JT, Achtman M.

J Infect Dis. 1989 Apr;159(4):686-700.

PMID:
2494268
24.

Purification and characterization of eight class 5 outer membrane protein variants from a clone of Neisseria meningitidis serogroup A.

Achtman M, Neibert M, Crowe BA, Strittmatter W, Kusecek B, Weyse E, Walsh MJ, Slawig B, Morelli G, Moll A, et al.

J Exp Med. 1988 Aug 1;168(2):507-25.

25.

Correlation of serological typing and clonal typing methods for Neisseria meningitidis sero-group A.

Crowe BA, Abdillahi H, Poolman JT, Achtman M.

J Med Microbiol. 1988 Jul;26(3):183-7. No abstract available.

PMID:
3134552
26.

Recent results on epidemic meningococcal meningitis.

Achtman M, Crowe BA, Olyhoek A, Strittmatter W, Morelli G.

J Med Microbiol. 1988 Jul;26(3):172-7. No abstract available.

PMID:
3134549
27.

Two monoclonal antibodies specific for serotype 4 antigen of Neisseria meningitidis.

Abdillahi H, Crowe BA, Achtman M, Poolman JT.

Eur J Clin Microbiol Infect Dis. 1988 Apr;7(2):293-6.

PMID:
2455642
28.

Comparison of clonal analysis and DNA restriction analysis for typing of Neisseria meningitidis.

Olyhoek T, Crowe BA, Wall RA, Achtman M.

Microb Pathog. 1988 Jan;4(1):45-51.

PMID:
3143892
29.

Clonal population structure of Neisseria meningitidis serogroup A isolated from epidemics and pandemics between 1915 and 1983.

Olyhoek T, Crowe BA, Achtman M.

Rev Infect Dis. 1987 Jul-Aug;9(4):665-92. Review.

PMID:
3125576
30.

A clonal analysis of Neisseria meningitidis serogroup A.

Crowe BA, Olyhoek T, Neumann B, Wall B, Hassan-King M, Greenwood B, Achtman M.

Antonie Van Leeuwenhoek. 1987;53(6):381-8.

PMID:
3130776
31.
32.
33.
34.

Supplemental Content

Loading ...
Support Center